Navigation Links
YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
Date:5/27/2010

Korea have demonstrated that nimotuzumab has the prospect of optimizing palliative care in this indication with initial stimulating results in this population. The primary objective of the trial is to evaluate the difference in Overall Survival between the arms with secondary endpoints being the differences in Time to Progression, Response Rate, Quality of Life, and Progression-Free Survival.

Both trials are currently open in Canada and are being extended into Europe, Korea, Singapore and India. The brain metastases trial is currently open in the United States and it is anticipated the NSCLC trial will begin to enroll patients in the United States shortly. Twelve sites are currently open with a total of 20 sites underway in North America with additional sites globally. Enrollment is targeted for completion toward the end of 2010.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company. Together with the products from YM BioSciences Australia, the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT387, a JAK 1/2 small molecule inhibitor; CYT997, a potent, vascular disrupting agent (VDA); and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
3. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
4. YM BioSciences third quarter 2010 operational and financial results
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
7. YM BioSciences announces controlled equity offering
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
9. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... Sunset, LA (PRWEB) July 21, 2014 ... poor sleep quality are closely correlated with depression. ... Institutes of Health: "About three quarters of ... present in about 40% of young depressed adults ... in females. The symptoms cause huge distress, have ...
(Date:7/18/2014)... 18, 2014  Neogen Corporation (Nasdaq: NEOG ... chief operating officer and president, has resigned, effective July ... a consultant going forward on special projects. His resignation ... in this position since September 2013. On an interim ... Herbert , who has been Neogen,s chief executive officer ...
(Date:7/18/2014)... & Cambridge, MA (PRWEB) July 18, 2014 ... headquartered in Budapest with US offices in Cambridge, ... - a combination Assay and Software product that ... for use on the Illumina® MiSeq sequencing platform. ... collaboration with The Children’s Hospital of Philadelphia (CHOP) ...
(Date:7/18/2014)... 18, 2014 Provia Laboratories announces the ... Advisory Board. Dr. Vaught has worked in the ... years. As one of the founding members of ... Repositories - in 1999, he served as its second ... , In 2005, Dr. Vaught began working with the ...
Breaking Biology Technology:Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3Omixon Launches Holotype HLA for NGS-based HLA Genotyping 2Omixon Launches Holotype HLA for NGS-based HLA Genotyping 3Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 2Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 3
... - Pipeline Update Conference Call and Webcast on May ... May 8 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... matrix, today reported financial,results for the three months ended ... a solid start as we significantly advanced both,our partnered ...
... ... U.S. ThermaCool NXT System Sales Grow 29% ... ), a leader in non-invasive tissue tightening in the aesthetic,industry, reported ... Revenue for the first quarter of 2008 was $16.2 million, ...
... Inc.,(Nasdaq: NUVO ) today announced first quarter 2008 financial ... first quarter ended March 31, 2008, Nuvelo reported a net ... net loss of $15.3,million, or $0.29 per share, for the ... due to $4.0 million in restructuring and facility,exit charges taken ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 First Quarter Financial Results 2Halozyme Therapeutics Reports 2008 First Quarter Financial Results 3Halozyme Therapeutics Reports 2008 First Quarter Financial Results 4Halozyme Therapeutics Reports 2008 First Quarter Financial Results 5Halozyme Therapeutics Reports 2008 First Quarter Financial Results 6Halozyme Therapeutics Reports 2008 First Quarter Financial Results 7Halozyme Therapeutics Reports 2008 First Quarter Financial Results 8Halozyme Therapeutics Reports 2008 First Quarter Financial Results 9Thermage Announces First Quarter 2008 Financial Results 2Thermage Announces First Quarter 2008 Financial Results 3Thermage Announces First Quarter 2008 Financial Results 4Thermage Announces First Quarter 2008 Financial Results 5Thermage Announces First Quarter 2008 Financial Results 6Thermage Announces First Quarter 2008 Financial Results 7Thermage Announces First Quarter 2008 Financial Results 8Thermage Announces First Quarter 2008 Financial Results 9Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 2Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 3Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 4Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 5Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008 6
(Date:7/22/2014)... the the genus of planthopper known as Conosimus, which ... recently discovered in the southern part of the Iberian ... of it appears in the open-access Journal of ... new species, Conosimus baenai , has been named ... to the taxonomy of Iberian Hemiptera. , Conosimus ...
(Date:7/21/2014)... As part of a multinational, collaborative effort, researchers ... have helped identify over 100 locations in the human ... what is the largest genomic study published on any ... Nature , point to biological mechanisms and pathways ... approaches to treating the disorder, which has seen little ...
(Date:7/21/2014)... researchers have detected genetic fragments of Middle East Respiratory ... holding a camel infected with the virus. The work, ... open-access journal of the American Society for Microbiology, indicates ... disease can be transmitted through the air. , MERS, ... has been identified in 699 people as of June ...
Breaking Biology News(10 mins):International team sheds new light on biology underlying schizophrenia 2International team sheds new light on biology underlying schizophrenia 3Middle East Respiratory Syndrome coronavirus detected in the air of a Saudi Arabian camel barn 2
... In our everyday life, we use gasoline, diesel, ... fossil oil through petrochemical refinery processes. However, this is ... resources. Furthermore, our world is facing problems associated with ... increasing use of fossil resources. One solution to address ...
... publisher BioMed Central revealed the winners of their 6th ... UK. Celebrating the very best research that has been ... guests attended the prestigious ceremony including leading researchers, shortlisted ... The winners were selected by internationally renowned judges ...
... a Smart car, with a shell large enough to double ... have found just such a specimen the fossilized remains ... is now Colombia. The turtle in question is ... of a group of side-necked turtles known as pelomedusoides. The ...
Cached Biology News:Production of chemicals without petroleum 2BioMed Central announces winners of 6th Annual Research Awards 2Ancient giant turtle fossil revealed 2
Contains L-glutamine...
... (PEBP) does not share significant homology ... PEBP is expressed in the central ... and stomach. One important role ... inhibitory activity against several serine proteases ...
...
Highly sensive assay for detecting apoptosis in living cells. See detailed descriptions above in K250-25....
Biology Products: